News

head uk2

The world of chitosan in 2016 & chitosan as adjuvant in vaccines

At the end of the year we want to give you an overview about chitosan-related publications in 2016 and in the second part we focus on a quite different application of chitosan – how human and veterinary vaccines could benefit from chitosan as adjuvant.

Publications about chitosan in 2016

In 2016, 2709 new articles about chitosan and chitosan derivates were published according to gopubmed. Throughout the whole year, China, United States and India were leaders in chitosan research. Researcher from Iran, Brazil, South Korea, and European Countries (Italy, Germany and France) were also industrious in publishing about chitosan. The journal Carbohydrate Polymers published by far the most articles (222) about chitosan. Overall, 96 reviews and 8 clinical trials reported about chitosan and chitosan derivates in 2016.

  top countries publications 2016

Top Journals    Publications
Carbohydr Polym 222
Int J Biol Macromol 154
Mater Sci Eng C Mater Biol Appl 83
Colloids Surf B Biointerfaces 47
Int J Pharm 38
Sci Rep 31
Acs Appl Mater Interfaces 22
Acta Biomater 20
J Colloid Interface Sci 19
Food Chem 19
 

Table: Journals and Countries, which published most chitosan-related articles in 2016. Source: GoPubMed

Most publications were about chitosan in connection to nanoparticles, pharmaceutical preparations and evaluation studies. The topic tissue was overtaken by polymers in 2016. The authors Jayakumar R. (4 articles), Khan S. (4), Stephen A. (3), Pintado M. (3) and Gübitz G. (3) published the most chitosan-related articles.

Top Terms Publications
Chitosan 1525
Nanoparticles 656
Pharmaceutical Preparations 506
Evaluation Studies as Topic 457
Polymers 354

Table: Top terms regarding chitosan in 2016. Source: GoPubMed

The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons

Carroll E. C., Jin L., Mori A., et al. Immunity 44, 597–608, March 15, 2016. doi: 10.1016/j.immuni.2016.02.004.

Development of new vaccines demands for better adjuvants, to trigger innate and adaptive immune response. Biocompatible chitosan is a promising alternative to widely used aluminum salts for injectable and mucosal vaccines. Researcher from Europe and USA investigated how the adjuvant chitosan (DDA 75-90%, Endotoxin ≤100 EU/g) induces cell-mediated immunity in mice.

RESULTS:

  • Promotion of dendritic cell maturation by induction of type I interferons (IFNs) in vitro
  • DC activation depends on cGAS and STING
  • ROS and cytoplasmic DNA are necessary for induction of type 1 IFNs by chitosan
  • Antigen-specific T helper 1 (Th1) response is enhanced

Conclusion: The study showed that induction of type I IFNs in dendritic cells are important for efficacy of chitosan as adjuvant. Type I IFNs are produced by activation of the cGAS-STING pathway.

https://www.ncbi.nlm.nih.gov/pubmed/26944200

Protective effect of a recombinant VHSV-G vaccine using poly(I:C) loaded nanoparticles as an adjuvant in zebrafish (Danio rerio) infection model

Kavaliauskis A., Arnemo M., Speth M. Developmental and comparative Immunology, 61:248-57, August 2016. doi: 10.1016/j.dci.2016.04.010.

The globally rising demand for fish requires an increase in industrial production by aquaculture. However, aquacultures are vulnerable for infectious diseases. A common infection is the viral hemorrhagic septicaemia virus (VHSV) like for freshwater salmoids. To improve efficacy of vaccines, application of adjuvants is often necessary. In this study, chitosan-poly (I:C) nanoparticels (NPs) were developed as non-specific adjuvant in antiviral vaccines. Physical parameters, biodistribution in vivo and in vitro as well as NP uptake by zebrafish leucocytes were characterized. Additionally, the authors from Oslo compared different vaccine formulations against VHSV (viral hemorrhagic septicaemia virus) with Chitosan-poly (I:C) nanoparticles as adjuvant:

  • recombinant glycoprotein G (rgpG) of VHSV + NPs
  • inactivated whole virus (iV) + NPs
  • rgpG + free poly (I:C)
  • rgpG + free chitosan

RESULTS:

  • Highest survival rate: iV plus NP adjuvant
  • Significant protection against VHSV by formulations with poly (I:C)

Conclusion: Chitosan-poly (I:C) NPs show a beneficial effect and might be an useful adjuvant for vaccines in industrial aquaculture.

www.ncbi.nlm.nih.gov/pubmed/27084059

chitosan, nanoparticles, vaccine, adjuvant, zebrafish model

Congress and fairs

Meet us in person 2023:

  • EASO Winterschool 2023, Wittenberg, Deutschland, 15.02.-18.02.2023
  • EUCHIS 2023, Siglufjörður, Island, 11.-14.09.2023
  • EPNOE 2023, Graz, Austria, 18.09.-22.09.2023
  • Asia Pacific Chitin and Chitosan Symposium 2023, Juju, Süd-Korea, 31.10.-03.11.2023
  • Bioeconomy Innovation Day, Brussels, Belgium, 16.11.2023

To arrange an appointment please contact Katja Richter via sales(at)medical-chitosan.com

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact | GTC / Terms of Use | Legal info | Copyright © 2023 Heppe Medical Chitosan GmbH | Privacy notice

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.